5-Amino-1MQ — Research Notes

What it is

5-Amino-1MQ (5-amino-1-methylquinolinium) is a synthetic small molecule and a selective inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme found primarily in white adipose tissue and the liver. Despite being marketed and sold alongside research peptides, 5-amino-1MQ is not a peptide in the traditional sense; it is a quinolinium salt with a molecular weight of approximately 159 Da, far smaller than even the shortest peptide chains. The compound was developed and characterized primarily by researchers at the University of Texas Medical Branch, with most published studies coming from the Watowich and Neelakantan laboratories.[1]

NNMT catalyzes the methylation of nicotinamide using S-adenosylmethionine (SAM) as a methyl donor, producing 1-methylnicotinamide and S-adenosylhomocysteine. In adipose tissue, elevated NNMT activity drains the cellular SAM pool and blunts NAD+ availability. By inhibiting this enzyme, 5-amino-1MQ is studied as a way to restore metabolic signaling capacity in adipose and muscle tissues without directly stimulating any hormone receptor.[5]

What researchers study it for

• Obesity and fat mass reduction The foundational 2018 study found that 5-amino-1MQ administration reduced body weight, white adipose tissue mass, and adipocyte size in diet-induced obese mice without altering food intake, providing the first evidence of efficacy for this compound class in an obesity model.[1]
• Metabolic dysfunction and insulin sensitivity A 2024 study examined 5-amino-1MQ (referred to as 5A1MQ) across multiple doses in diet-induced obese mice and found dose-dependent improvements in glucose tolerance and insulin sensitivity, along with reductions in liver fat accumulation and macrophage infiltration in adipose tissue; subcutaneous administration was also characterized pharmacokinetically in this work.[3]
• Aged muscle stem cell activation and regeneration Researchers have studied whether NNMT inhibition can reverse the senescence-associated decline in muscle stem cells; a 2019 study found that treatment in 24-month-old mice rescued satellite cell activity and produced substantially greater myofiber cross-sectional area and peak torque recovery after injury compared to vehicle-treated controls.[2]
• Diet and microbiome interactions A 2022 study in Scientific Reports explored the combination of NNMT inhibition with caloric restriction in obese mice; the combination normalized adiposity more rapidly than diet alone and produced a distinct gut microbiome pattern, with notable shifts in Erysipelatoclostridium and Lactobacillus populations.[4]
• NNMT as a metabolic target: foundational mechanism The target biology underlying 5-amino-1MQ research was established by a 2014 Nature study showing that NNMT expression is elevated in adipose tissue and liver of obese and diabetic mice, and that genetic knockdown of NNMT protects against diet-induced obesity by altering tissue SAM and NAD+ availability; this foundational work validated NNMT as a therapeutic target before selective inhibitors were available.[5]

Research context

The published evidence base for 5-amino-1MQ is narrow by the standards of this site. Virtually all experimental work comes from a single research group at the University of Texas Medical Branch, with most studies published between 2018 and 2024. All available studies are preclinical, conducted in rodent models of diet-induced obesity or aged mice; no human clinical trials have been published as of 2026.[1][3] The reliance on a single laboratory means independent replication is limited, which is an important caveat for evaluating confidence in the reported effects.

Within those boundaries, the preclinical results are consistent across multiple endpoints: body weight, adipose mass, glucose handling, and muscle regeneration all showed positive signals in rodent models using the same compound class.[2][4] The 2024 pharmacokinetic study added practical detail about subcutaneous dosing and tissue distribution in mice, which informs how researchers design experiments, but does not constitute human safety or efficacy data. For a compound sold in a market that mostly discusses it alongside traditional peptides, it is worth noting that 5-amino-1MQ's mechanism, structure, and research maturity are quite different from compounds like BPC-157 or GHK-Cu.

Typical research parameters

Related research notes